
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Contemporary Pediatrics' Editor-in-Chief reflects on Kawasaki disease and what it means when a disease remains an enigma for so long after discovery.






